The Filing Desk

Lakefront Biotherapeutics NV

LKFT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

LKFT · Last close · November 19, 2026
$33.39

Lakefront Biotherapeutics NV's revenue rose 303.5% to €1.1 billion in fiscal 2025. Its operating margin was 26.5%, up from −68.3% a year earlier. Free cash flow was −€271 million.

GALAPAGOS NV Latest fiscal year ended December 31, 2025 20-F filed March 26, 2026 · 0001104659-26-035163 Updated
Revenue
€1.1B
303.5%
Operating margin
26.5%
94.9 pts
Net income
€321M
333.1%
Free cash flow
−€271M
 
Return on equity
10.5%
7.9 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. Lakefront Biotherapeutics NV is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in EUR, as it reports them: they aren't converted to US dollars.

Income statement

Revenue and net income
EUR billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
EUR billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 17.5% a year and net income 21.9% a year, as new shares raised the share count by 39% and diluted each share's earnings.

Diluted earnings per share
EUR per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
EUR billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
EUR billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments4,7034,0943,6843,1182,998
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−14.8x−19.0x−49.9x−206.7x285.3x
Current ratio8.6x8.1x9.0x10.0x20.1x
Quick ratio8.6x8.0x8.8x9.8x20.0x
EUR millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
EUR billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
EUR billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
EUR billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−177.8%−107.2%279.1%
Altman Z''6.746.8126.33
Accruals ratio13.6%9.3%15.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailFailFail
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't riseFailFailPass
Gross margin rose——Pass
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Lakefront Biotherapeutics NV side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Lakefront Biotherapeutics NVFY25303.5%26.5%−24.4%———
NovavaxFY2564.7%40.3%−22.3%—−1.0x5Compare
Legend BiotechFY2564.0%−13.3%−12.5%−14.6%—2Compare
HalozymeFY2537.5%33.6%46.1%19.2%4.2x5Compare
BioCryst PharmaceuticalsFY2594.1%39.0%39.4%—−0.8x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1301272798354782342412402761,112
Revenue growth227.4%−1.9%119.3%199.6%−42.7%−51.0%2.9%−0.6%15.0%303.5%
Gross profit—————233229—2411,082
Research and development140218316420524320270241336459
Operating income−12−90−47369−179−172−131−88−188295
Net income54−116−29150−305−103−21821274321
Diluted EPS (EUR)1.14−2.34−0.562.49−4.69−1.58−3.323.211.124.87
Diluted shares (millions)47505258656666666666
Cash flow
Cash from operations239−147−1423,209−427−504−500−406−320−258
Capital expenditure451022425427191714
Free cash flow235−152−1533,186−470−558−528−425−337−271
Dividends paid0000000000
Share buybacks0000000000
Acquisitions000000115700
Stock-based compensation11162738807188572024
Balance sheet at fiscal year end
Cash and short-term investments9731,1511,2915,7815,1624,7034,0943,6843,1182,998
Debt incl. finance leases——————————
Total assets1,0831,2861,4406,0695,7185,1934,7344,3574,1363,406
Total liabilities3252742253,1933,0472,5502,2081,5621,239171
Shareholders' equity7591,0121,2142,8762,6702,6432,5262,7962,8973,236
Margins and ratios
Gross margin—————99.3%95.0%—87.3%97.3%
Operating margin−8.9%−70.7%−16.9%44.2%−37.4%−73.2%−54.3%−36.8%−68.3%26.5%
Net margin41.7%−91.0%−10.5%17.9%−63.9%−44.0%−90.4%88.3%26.9%28.9%
Free cash flow margin181.4%−119.9%−54.9%381.6%−98.3%−238.1%−218.8%−177.2%−122.2%−24.4%
Rule of 40 (growth + FCF margin)408.8%−121.8%64.4%581.2%−141.0%−289.1%−215.9%−177.8%−107.2%279.1%
Return on capital——————————
Return on equity9.6%−13.1%−2.6%7.3%−11.0%−3.9%−8.4%8.0%2.6%10.5%
Return on assets7.1%−9.8%−2.1%4.0%−5.2%−1.9%−4.4%4.7%1.7%8.5%
Net debt to EBITDA——————————
EUR millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, EUR millions)
Source: Lakefront Biotherapeutics NV's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Lakefront Biotherapeutics NV.